Pharmacoeconomic Aspects of Using New Generation Drugs Of PCSK-9 Inhibitor and Acting on The Effect of Ribonucleic Acid Interference Classes in The Treatment of Patients With Hypercholesterolemia at High Risk of Cardiovascular Events

Aim     Clinical and economic analysis of the feasibility of using new-generation drugs of the PCSK-9 inhibitor class (alirocumab and evolocumab) and the drugs that utilize in their action the effect of ribonucleic acid interference (inclisiran) in the treatment of patients with a high risk of cardiovascular events in medical organizations of the Moscow Region (MR).

Material and methods            Based on statistical and literature data on morbidity, as well as data from real-life practice about using alirocumab, evolocumab, and inclisiran in medical organizations of the MR, populations of patients with hypercholesterolemia and cardiovascular pathology were identified in that region. Two analytical models were developed that include the structure and number of patients receiving a combination therapy (high-dose statins + ezetimibe + alirocumab/evolocumab/inclisiran). To estimate the economic feasibility of the treatment with innovative drugs, direct medical costs were calculated for various therapeutic regimens. The cost of pharmacotherapy was calculated per patient per one-year course. A budget impact analysis (BIA) and a sensitivity analysis of the results were performed. The modeling period of the study was 3 years.

Results            The number of patients in different populations receiving the combination therapy will be 12,228 and 895 people in the first year, and 12,973 and 950 people in the third year, taking into account the determined increase in the patient number. The total costs of treating one patient with hypercholesterolemia and cardiovascular diseases during the first year of therapy with inclisiran are 23.31 and 27.66% lower than with evolocumab and alirocumab, respectively. The BIA revealed a slight increase in the total cost of treating patients in each population (by 1.39 and 1.69% compared to 2024). The increase in the regional budget will be related only with the annual increase in the number of patients with hypercholesterolemia. The sensitivity analysis showed the robustness of the results to changes in the initial parameter values.

Conclusion      The treatment of patients with dyslipidemia and high risk of cardiovascular events with alirocumab/evolocumab/inclisiran as part of the combination therapy is an economically justified strategy in the settings of the regional healthcare system.

1. Zafiraki V.K., Namitokov A.M., Kosmacheva E.D. Familial Hypercholesterolemia: Diagnostic Issues and Therapeutic Possibilities. Kuban Scientific Medical Bulletin. 2019;26(1):175–86. DOI: 10.25207/1608-6228-2019-26-1-175-186

2. Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet. 2004;364(9438):937–52. DOI: 10.1016/S0140-6736(04)17018-9

3. Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen M-R, Wiklund O et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217(1):3–46. PMID: 21882396

4. Sergienko I.V., Nedogoda S.V., Vertkin A.L., Glezer M.G., Gurevich V.S., Gornyakova N.B. et al. Current issues of increasing the availability of innovative therapy and organizing medical care for patients with atherosclerotic cardiovascular diseases in the Russian Federation. Council of Experts. Atherosclerosis and Dyslipidemias. 2022;4(49):54–61. DOI: 10.34687/2219-8202.JAD.2022.04.0006

5. Begoun D.N., Morozova T.A., Surikova A.V. Diseases of the circulatory system as a medical and social problem. Young Scientist. 2019;8(246):25–8.

6. Puzin S.N., Shurgaya M.A., Lyalina I.V., Fizitskaya V.D. Medical and social expertise in diseases of the circulatory system: a review of updated classifications and criteria. Pedagogy of professional medical education. 2020;1:67–78.

7. Bessonova T.O., Mukhortova P.A., Teryan R.A., Bagdasarov A.D., Musina N.Z. Cost-effectiveness analysis of using atorvastatin, simvastatin, ezetimibe, alirocumab, evolocumab, inclisiran in adults with very high cardiovascular risk under the preferential drug provision program. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2023;16(1):17–34. DOI: 10.17749/2070-4909/farmakoekonomika.2023.173

8. Fedorova N.V., Sedykh D.Yu., Kashtalap V.V., Chesnokova L.Yu., Gruzdeva O.V., Barbarash O.L. Intensification of lipid-lowering therapy in patients with acute coronary syndrome. Complex Issues of Cardiovascular Diseases. 2019;8(S4):121–9. DOI: 10.17802/2306-1278-2019-8-4S-121-129

9. Omelyanovsky V.V., Avksentyeva M.V., Sura M.V., Khachatryan G.R., Gerasimova K.V., Ivakhnenko O.I. et al. Methodological recommendations for assessing the impact on the budget in the framework of the implementation of the program of state guarantees of free medical care to citizens (new edition). Approved by the order of the Federal State Budgetary Institution ‘TSEKKMP’ of the Ministry of Health of the Russian Federation dated December 29, 2018 No. 242-od. Moscow. 2018. 40p. Av. at: https://rosmedex.ru/pub?ysclid=mbj5u5rsbk96250853. 2018.

10. PharmIndex.RU. Search and order medicines in pharmacies in Russia. [Internet] Available at: https://www.pharmindex.ru/

11. Ministry of Health of the Russian Federation. Clinical guidelines “Lipid metabolism disorders”. Av. at: https://cr.minzdrav.gov.ru/viewcr/752_1

12. Averkov O.V., Arutyunyan G.K., Duplyakov D.V., Konstantinova E.V., Nikulina N.N., Shakhnovich R.M. et al. 2024 Clinical practice guidelines for Acute myocardial infarction with ST segment elevation electrocardiogram. Russian Journal of Cardiology. 2025;30(3):121–207. DOI: 10.15829/1560-4071-2025-6306

13. Ministry of Health of the Russian Federation. Clinical recomendations. Acute coronary syndrome without ST segment elevation electrocardiogram. 2024. Av. at: https://scardio.ru/content/Guidelines/2024_09_26.pdf.

14. Ministry of Health of the Russian Federation. Clinical recommendations. Stable coronary heart disease. 2020. Av. at: https://cr.minzdrav. gov.ru/preview-cr/155_1.

15. State Register of medicines. Instructions for the medical use of the drug Praluent. Av. at: https://grls.minzdrav.gov.ru/Grls_View_ v2.aspx?routingGuid=65a43bd7-e7ef-462b-a5d4-7bf683cdbcf9

16. State Register of medicines. Instructions for the medical use of the drug Repata. Av. at: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=0936e208-119c-4824-b55b-9e8214d95308

17. State Register of medicines. Instructions for the medical use of the drug Sibrava (inclusiran). Av. at: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=6f4a2a8b-be49-4fad-98e7-e3e4ddfa2b2d

18. State Register of medicines. Instructions for the medical use of the drug Atorvastatin. Av. at: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=03ef094b-02e5-463d-bc7414346243da18

19. State Register of medicines. Instructions for the medical use of the drug Ezetimibe. Av. at: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=1ba2993f-3d69-4f7f-853c-690522d26100

20. Khan SA, Naz A, Qamar Masood M, Shah R. Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia. The American Journal of Cardiology. 2020;134:69–73. DOI: 10.1016/j.amjcard.2020.08.018

21. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine. 2017;376(18):1713–22. DOI: 10.1056/NEJMoa1615664

22. Luo M, Liu Y, Xu X, Liu K, Shen C, Hu H et al. Efficacy and safety of inclisiran in stroke or cerebrovascular disease prevention: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Pharmacology. 2023;14:1158274. DOI: 10.3389/fphar.2023.1158274

23. Geng Q, Li X, Sun Q, Wang Z. Efficacy and safety of PCSK9 inhibition in cardiovascular disease: a meta-analysis of 45 randomized controlled trials. Cardiology Journal. 2022;29(4):574–81. DOI: 10.5603/ CJ.a2021.0110

24. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. New England Journal of Medicine. 2018;379(22):2097–107. DOI: 10.1056/NEJMoa1801174

25. Ministry of Health of the Russian Federation. Order No. 612n dated 10.06.2021 «On approval of the standard of medical care for adults with acute myocardial infarction with ST segment elevation of the electrocardiogram (diagnosis, treatment and dispensary observation)». Av. at: https://minjust.consultant.ru/documents/27425?ysclid=mbj8ohiinq586681987

26. Ministry of Health of the Moscow Region. Tariff agreement for the implementation of the Moscow regional compulsory medical insurance program for 2024. Av. at: https://mz.mosreg.ru/ov/komissiya-po-razrabotke-moskovskoi-oblastnoi-programmy-obyazatelnogo-medicinskogo-strakhovaniya-tarifnayakomissiya/05-02-2024-13-36-18-tarifnoe-soglashenie-po-realizatsii-moskovskoy-obl?ysclid=mbj911nikp36955957727. Ministry of Health of the Russian Federation. Methodological recommendations on ways to pay for medical care at the expense of compulsory medical insurance. Letter from the Ministry of Health of the Russian Federation dated 19.02.2024. Av. at: https://www.garant.ru/products/ipo/prime/doc/408486489/

27. Federal State Statistics Service. Moscow region in numbers. A short statistical collection. Av. at: https://77.rosstat.gov.ru/storage/mediabank/Московская область в цифрах 2024.pdf

28. Boytsov S.A., Shakhnovich R.M., Tereschenko S.N., Erlikh A.D., Kukava N.G., Pevsner D.V. et al. The prevalence of hyperlipidemia and features of lipid-lowering therapy in patients with myocardial infarction according to the Russian register of acute myocardial infarction REGION-MI. Kardiologiia. 2022;62(7):12–22. DOI: 10.18087/cardio.2022.7.n2051

29. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen M-R, Wiklund O et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal. 2011;32(14):1769–818. DOI: 10.1093/eurheartj/ehr158

30. Akhmedzhanov N.M., Nebieridze D.V., Safaryan A.S., Vygodin V.A., Shuraev A.Yu., Tkacheva O.N. et al. Analysis of hypercholesterolemia prevalence in the outpatient practice (according to the ARGO study): part I. Rational Pharmacotherapy in Cardiology. 2015;11(3):253–60. DOI: 10.20996/1819-6446-2015-11-3-253-260

31. Aronov D.M., Arabidze G.G., Akhmedzhanov N.M., Balakhonova T.V., Boytsov S.A., Bubnova M.G. et al. Diagnosis and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations. V revision. Russian Journal of Cardiology. 2012;17(4 S1):2–32.

32. Metelskaya V.A., Shalnova S.A., Deev A.D., Perova N.V., Gomyranova N.V., Litinskaya O.A. et al. Analysis of atherogenic dyslipidemias prevalence among population of Russian Federation (results of the ESSE-RF Study). Prevention Medicine. 2016;19(1):15–23. DOI: 10.17116/profmed201619115-23

33. Decree of the Government of the Russian Federation No. 10-r dated 15.01.2025 “On Amendments to Decree of the Government of the Russian Federation No. 2406-r dated 12.10.2019”. Av. at: https://www.zakonrf.info/rasporiazhenie-pravitelstvo-rf-10-r-15012025/